[1]
N. Abbarin, “PASI Improvement in the First 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE Guselkumab Clinical Trials”, J of Skin, vol. 7, no. 6, p. s237, Nov. 2023.